For research use only. Not for therapeutic Use.
Tenatumomab（Cat No.:I042121）is a monoclonal antibody targeting the protein CD19, which is expressed on the surface of B-cells, including malignant B-cells in certain cancers. It is being explored primarily in the treatment of hematologic malignancies, such as B-cell non-Hodgkin lymphoma and leukemia. By binding to CD19, Tenatumomab helps to target and destroy abnormal B-cells, potentially reducing tumor burden. Clinical trials have shown its potential in combination with other therapies to improve patient outcomes. Ongoing research is assessing its safety, efficacy, and optimal use in cancer treatment.
| Catalog Number | I042121 |
| CAS Number | 1412891-40-7 |
| Purity | ≥95% |
